High expression of human leukocyte antigen-G is associated with a poor prognosis in patients with PDAC

Current Molecular Medicine

Volumn 15, Issue 4, 2015, Pages 360-367

  Xu, Y F ^a,b   Lu, Y ^a,b   Cheng, H ^a,b   Jiang, J ^a,b   Xu, J ^a,b   Long, J ^a,b   Liu, L ^a,b   Ni, Q ^a,b   Liu, C ^a,b   Yu, X J ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

HLA G; Immune escape; Overall survival; Pancreatic ductal adenocarcinoma (PDAC); Prognosis

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CD28 ANTIGEN; CD8 ANTIGEN; HLA G ANTIGEN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; T LYMPHOCYTE SUBPOPULATION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR ESCAPE; WESTERN BLOTTING; ADENOCARCINOMA; BLOOD; CD8+ T LYMPHOCYTE; GENETICS; IMMUNOLOGY; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD28; BIOMARKERS; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; HLA-G ANTIGENS; HUMANS; LYMPHATIC METASTASIS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR ESCAPE;

EID: 84930984885     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150401102218     Document Type: Article

References (44)

1. [1] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. [2] Long J, Luo GP, Xiao ZW, et al. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett 2014; 346: 273-7.
3. [3] Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 2012; 152: S43-9.
4. [4] Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology 2013; 144: 1316-26.
5. [5] Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-71.
6. [6] Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
7. [7] Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.
8. [8] Sideras K, Braat H, Kwekkeboom J, et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 2014; 40: 513-22.
9. [9] Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol 2012; 2012: 926321.
10. [10] Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15: 971-9.
11. [11] Errico A. Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nat Rev Clin Oncol 2015; 12: 63.
12. [12] Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med 2015; 372: 311-9.
13. [13] Sun TW, Gao Q, Qiu SJ, et al. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol Immunother 2012; 61: 2171-82.
14. [14] Cai MY, Xu YF, Qiu SJ, et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res 2009; 15: 4686-93.
15. [15] Curigliano G, Criscitiello C, Gelao L, Goldhirsch A. Molecular pathways: human leukocyte antigen G (HLA-G). Clin Cancer Res 2013; 19: 5564-71.
16. [16] Rouas-Freiss N, Moreau P, LeMaoult J, Carosella ED. The dual role of HLA-G in cancer. J Immunol Res 2014; 2014: 359748.
17. [17] Bukur J, Jasinski S, Seliger B. The role of classical and nonclassical HLA class I antigens in human tumors. Semin Cancer Biol 2012; 22: 350-8.
18. [18] Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci U S A 1987; 84: 9145-9.
19. [19] Kovats S, Main EK, Librach C, et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248: 220-3.
20. [20] Paul P, Rouas-Freiss N, Khalil-Daher I, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998; 95: 4510-5.
21. [21] Zheng J, Xu C, Chu D, et al. Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis. Immunol Lett 2014; 161: 13-9.
22. [22] Du L, Xiao X, Wang C, et al. Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Cancer Sci 2011; 102: 1272-80.
23. [23] Ye SR, Yang H, Li K, et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007; 20: 375-83.
24. [24] Xu YF, Lu Y, Cheng H, et al. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. Pancreatology 2014; 14: 295-301.
25. [25] Liu L, Xu HX, Wang WQ, et al. Cavin-1 is essential for the tumorpromoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene 2014; 33: 2728-36.
26. [26] Shi S, Lu Y, Qin Y, et al. miR-1247 is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins. Curr Mol Med 2014; 14: 316-27.
27. [27] Lu Y, Liu C, Cheng H, et al. Stathmin, interacting with NfkappaB, promotes tumor growth and predicts poor prognosis of pancreatic cancer. Curr Mol Med 2014; 14: 328-39.
28. [28] Xu J, Zhu W, Xu W, et al. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin. Curr Mol Med 2013; 13: 387-400.
29. [29] Yan WH. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocr Metab Immune Disord Drug Targets 2011; 11: 76-89.
30. [30] Yan WH, Fan LA. Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition. Cell Res 2005; 15: 176-82.
31. [31] Amiot L, Vu N, Rauch M, et al. Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis. J Hepatol 2014; 60: 245-52.
32. [32] Naji A, Menier C, Morandi F, et al. Binding of HLA-G to ITIMbearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol 2014; 192: 1536-46.
33. [33] Agaugue S, Carosella ED, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 2011; 117: 7021-31.
34. [34] Yan WH. Human leukocyte antigen-G in cancer: are they clinically relevant? Cancer Lett 2011; 311: 123-30.
35. [35] Nag K, Chaudhary A. Mediators of Tyrosine Phosphorylation in Innate Immunity: From Host Defense to Inflammation onto Oncogenesis. Curr Signal Transduct Ther 2009; 4: 76-81.
36. [36] von Manstein V, Yang CM, Richter D, et al. Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops. Curr Signal Transduct Ther 2013; 8: 193-202.
37. [37] Zidi I, Ben Amor N. Nanoparticles targeting HLA-G for gene therapy in cancer. Med Oncol 2012; 29: 1384-90.
38. [38] Gros F, Sebti Y, de Guibert S, et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 2006; 8: 223-30.
39. [39] Morandi F, Rouas-Freiss N, Pistoia V. The emerging role of soluble HLA-G in the control of chemotaxis. Cytokine Growth Factor Rev 2014; 25: 327-35.
40. [40] Morandi F, Ferretti E, Castriconi R, et al. Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood 2011; 118: 5840-50.
41. [41] Gonzalez A, Rebmann V, LeMaoult J, et al. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci 2012; 49: 63-84.
42. [42] Schutt P, Schutt B, Switala M, et al. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol 2010; 71: 489-95.
43. [43] Riteau B, Faure F, Menier C, et al. Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol 2003; 64: 1064-72.
44. [44] Alegre E, Howangyin KY, Favier B, et al. Membrane redistributions through multi-intercellular exchanges and serial trogocytosis. Cell Res 2010; 20: 1239-51.